Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Seagen Inc.
H. Lee Moffitt Cancer Center and Research Institute
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
Treeline Biosciences, Inc.
Mayo Clinic
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
Ohio State University Comprehensive Cancer Center
University of Alabama at Birmingham
Boston Immune Technologies and Therapeutics
Mayo Clinic
Thomas Jefferson University
City of Hope Medical Center
Fox Chase Cancer Center
City of Hope Medical Center
Bio-Path Holdings, Inc.
Daiichi Sankyo
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
Mundipharma Research Limited
Stanford University
Stanford University
Karyopharm Therapeutics Inc
Genzada Pharmaceuticals USA, Inc.
Sorrento Therapeutics, Inc.
Jiangsu Simcere Pharmaceutical Co., Ltd.
National Institutes of Health Clinical Center (CC)
Peter MacCallum Cancer Centre, Australia
National Institutes of Health Clinical Center (CC)
University of Zurich
4SC AG
Fred Hutchinson Cancer Center
University of Michigan Rogel Cancer Center
Innate Pharma
Barbara Ann Karmanos Cancer Institute
miRagen Therapeutics, Inc.
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
University of California, San Francisco
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
Rhizen Pharmaceuticals SA